Driven by the dual forces of policy support and innovation, the domestic pharmaceutical industry is accelerating its recovery. On August 18, Hong Kong-listed leading pharmaceutical company Sino Biopharm (01177.HK) announced its 2025 semi-annual results. In the first half of the year, the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion, representing year-on-year increases of 10.7% and 140.2%, respectively, marking three consecutive reporting periods of stable double-digit growth.

China Securities Journal, cs.com.cn (Reporter: Meng Peijia) - The 2025 semi-annual results report disclosed by Sino Biopharm on August 18 shows that the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion in the first half of the year, representing year-on-year increases of 10.7% and 140.2%, respectively, achieving double-digit performance growth. The company proposes to distribute a dividend of RMB 820 million for the first half of 2025, an increase of over 60% compared to the same period last year.

Xinhua Finance, Nanjing, August 18 (Reporter: Zhu Cheng) - The 2025 semi-annual results report disclosed by Sino Biopharm on August 18 shows that the company achieved revenue of RMB 17.57 billion and net profit attributable to owners of the parent of RMB 3.39 billion, representing year-on-year increases of 10.7% and 140.2%, respectively.

Recently, the biosimilar Adalimumab (Taibowei®) from Chia Tai Tianqing, a member company of Sino Biopharm (1177.HK), was officially approved for marketing by the Algerian Medicines Agency. This will bring a high-quality and affordable new treatment option to patients with autoimmune disorders in countries participating in the "Belt and Road" initiative.

On the morning of July 17, Sino Biopharm, the parent company of Chia Tai Tianqing, held a briefing on the wholly-owned acquisition of LaNova Medicines.

After market close on July 15, Sino Biopharm announced that it will acquire a 95.09% stake in Shanghai-based LaNova Medicines for a total price of approximately USD 500 million. Combined with the 4.91% stake already acquired through participation in LaNova's Series C financing, LaNova Medicines will become a wholly-owned subsidiary of Sino Biopharm upon completion of the transaction.

On July 15, Sino Biopharm (1177.HK) made a major announcement that it will acquire 100% of LaNova Medicines Ltd. for a net consideration of approximately US$500 million.

The ecosystem of China's innovative drugs has taken another step towards diversification. On the afternoon of July 15, Sino Biopharm announced that it will acquire a 95.09% stake in Shanghai-based LaNova Medicines for a total price of approximately USD 500 million.

China Securities Journal, cs.com.cn (Reporter: Meng Peijia) - On July 15, Sino Biopharm announced that it will acquire a 95.09% stake in Shanghai-based LaNova Medicines for a total price of approximately USD 500 million. Combined with the 4.91% stake acquired through participation in LaNova's Series C financing, LaNova Medicines will become a wholly-owned subsidiary of Sino Biopharm upon completion of the transaction.

Sino Biopharm will acquire a 95.09% stake in Shanghai-based LaNova Medicines for a total price of approximately USD 500 million. Upon completion of the transaction, LaNova Medicines will become a wholly-owned subsidiary of Sino Biopharm. LaNova Medicines' total out-licensing deals in the past three years amounted to nearly RMB 30 billion.